CSL Behring dominates CYTOGAM market as post-marketing research expands

The CYTOGAM market is highly concentrated, with CSL Limited’s CSL Behring unit holding 100% of global sales in 2024, according to The Business Research Company. A new report says post-marketing research, plasma supply strength and transplant-focused clinical work are shaping competition in the niche plasma-derived therapy market.

Why it matters: - The CYTOGAM market is a niche but strategically important part of transplant medicine because it supports cytomegalovirus prevention in vulnerable patients. - A market with one dominant supplier highlights heavy barriers to entry in plasma-derived biologics, including sourcing, manufacturing, quality control and regulatory requirements. - The report points to growing demand for transplant-associated infection management and specialized immunotherapy solutions.

What happened: - The Business Research Company released its 2026 CYTOGAM market report covering market size, trends and a global forecast for 2026-2035. - CSL Limited, through CSL Behring, led global CYTOGAM sales in 2024 with a 100% market share. - The report identifies CSL Limited as the only major company operating in the CYTOGAM market. - The report also says the market was highly concentrated in 2024, with the top player accounting for all revenue.

The details: - CSL Behring’s immunoglobulin portfolio underpins its position in plasma-derived treatment offerings, manufacturing expertise and distribution reliability. - The report says the company’s market position is supported by established plasma collection infrastructure and long-standing experience in plasma-derived therapeutics. - Major raw material suppliers named in the report include CSL Plasma, Grifols, Octapharma Plasma, Kedplasma, BioLife Plasma Services, ADMA Biologics, LFB Group, Sanquin Plasma Products, Biotest AG, China Biologic Products Holdings, Hualan Biological Engineering, Shanghai RAAS Blood Products, Japan Blood Products Organization, GC Biopharma, SK Plasma, Intas Pharmaceuticals Plasma Division, Bharat Serums and Vaccines, Reliance Life Sciences and Takeda Plasma Power. - Major wholesalers and distributors listed include Cencora, McKesson Corporation, Cardinal Health, Morris & Dickson, FFF Enterprises, Anda Inc., CuraScript SD, BioCareSD, ASD Healthcare, Pharmaceutical Associates Inc., Medline Industries, Owens & Minor, Henry Schein, Concordance Healthcare Solutions, McKesson Plasma and Biologics, Besse Medical, NDC Inc., Matrix HealthCare, Accredo Health Group and CVS Specialty. - Major end users listed include Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Cedars-Sinai Medical Center, Mount Sinai Health System, NewYork-Presbyterian Hospital, Stanford Health Care, UCLA Health, Northwestern Memorial Hospital, Houston Methodist Hospital, Duke University Hospital, UCSF Health, Memorial Sloan Kettering Cancer Center, Mayo Clinic Transplant Centers, University of Michigan Health, Keck Medicine of USC and NYU Langone Health. - The report says the market’s concentration reflects manufacturing and regulatory entry barriers tied to plasma sourcing, biologics production complexity and quality assurance.

Between the lines: - Kamada Ltd. launched a post-marketing research program for CYTOGAM in May 2025, signaling that evidence generation is becoming a key competitive lever even in a concentrated market. - The program includes 10 studies conducted with leading U.S. physicians and key opinion leaders. - The research agenda focuses on late-onset CMV prevention, alternative dosing strategies, mechanism-of-action evaluation, health economic analysis and possible future uses. - That mix suggests companies are trying to deepen clinical utility claims and strengthen adoption in solid organ transplantation. - The report’s strategy list points to a market where operational scale, clinical collaboration and plasma collection capacity matter as much as product formulation.

What's next: - The report says leading companies are expected to keep investing in manufacturing optimization, therapeutic portfolio strength and operational scale. - Post-marketing studies are likely to remain central to product positioning and transplant medicine evidence building. - The broader plasma-derived therapeutics ecosystem appears set to stay focused on supply reliability, compliance and specialized treatment support.

The bottom line: - CYTOGAM is a one-player market for now, and competition is shifting toward evidence generation, plasma supply strength and transplant-focused clinical credibility.